Gastroenterology Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gastroenterology Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Esophageal Cancer
Esophageal cancer sensitivity to peplomycin predicted by calpain/calpastatin expression levels
August 7th, 2006
The chemosensitivity of esophageal cancer to peplomycin (PEP) could be predicted by calpain/calpastatin expression levels. "Chemosensitivity to anticancer drugs was compared between two human esophageal carcinoma cell lines, T.Tn and YES-6 cells. T.Tn cells were more resistant than YES-6 cells to PEP but not to the other anticancer drugs such as camptothecin, mitomycin C and cytosine arabinoside. Western blot analysis showed higher expression levels of m-calpain and activated mu-calpain in T.Tn cells than in YES-6 cells. On the other hand, YES-6 cells showed a high expression level of calpastatin, which is a calpain-specific endogenous inhibitor," investigators in Japan...
Source: Gastroenterology Week (2006-08-07)
|
